 Acasti Pharma Inc. Acasti or the Company NASDAQ: ACST TSX-V: ACST, a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre omega-3 phospholipid for the treatment of severe hypertriglyceridemia sHTG triglyceride blood levels from 500 mgdL to 1500 mgdL, today provided a business and TRILOGY Phase 3 Clinical Program update, and announced its operating and financial results for the fiscal year ended March 31, 2020. The Company also reported a phenomenon that it refers to as Pre-Randomization Triglyceride TG Normalization that occurred between the screening and randomization periods of the study during qualification, and prior to patients starting on drug or placebo. 